Abemaciclib in combination with an aromatase inhibitor or fulvestrant is indicated for treating women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer (MBC) as initial endocrine therapy (ET), or in women who have received prior ET.1* In this exclusive video, Dr. Chandrakanth M.V. discusses the real-world clinical experience of abemaciclib in HR+/HER2- MBC patients with visceral, liver, and bone marrow metastasis.
Reference 1. Abridged Pack Insert- Abemaciclib (Ramiven®) *Please refer to the prescribing information for details